ReviewMicrobiology and molecular biology reviews : MMBR2014
Latent tuberculosis infection: myths, models, and molecular mechanisms.
Review in Microbiology and molecular biology reviews : MMBR, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 129 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
129 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Cardiovascular morbidity and mortality among persons diagnosed with tuberculosis: A systematic review and meta-analysis.PloS one · 2020Pooled it
- Tryptophan catabolism reflects disease activity in human tuberculosis.JCI insight · 2020Trial
- Latent tuberculosis infection is associated with increased unstimulated levels of interferon-gamma in Lima, Peru.PloS one · 2018Trial
- LTBI Prevalence and Risk Factors in Field Practice Areas of a Tertiary Care Hospital, Jodhpur, Rajasthan.Indian journal of community medicine : official publication of Indian Association of Preventive & Social Medicine · 2026Article
- Modulation of pulmonary IL-21 expression during latent TB and M. tuberculosis/SIV coinfection.JCI insight · 2026Article
- Sodium Alendronate-Modified PLGA-mPEG Nanomicelles Loaded with Rifapentine for Targeted Delivery to Bone Tissue.Pharmaceutics · 2026Article
- Whole Genome Sequencing of ClinicalInternational journal of molecular sciences · 2025Article
- Discovery of highly potent α-keto ester-based peptidomimetic inhibitors of the Hip1 protease for the treatment ofEuropean journal of medicinal chemistry reports · 2025Article
- Short- and long-term exposure to ambient air pollution and greenness in relation to pulmonary tuberculosis incidence.Scientific reports · 2025Article
- Insights into Natural Products from Marine-Derived Fungi with Antimycobacterial Properties: Opportunities and Challenges.Marine drugs · 2025Review
- Reactivation of Latent Tuberculosis Following COVID-19 and Epstein-Barr Virus Coinfection: A Case Report.Pathogens (Basel, Switzerland) · 2025Article
- Reprogramming the host: Mycobacterium tuberculosis as a silent architect of the immuno-tumoral.Frontiers in cellular and infection microbiology · 2025Review
- Expression of Resuscitation-Promoting Factor C Stimulates the Growth ofInternational journal of microbiology · 2025Article
- Physiological stage-dependent effects ofFrontiers in microbiology · 2025Article
- Factors associated with indeterminate QuantiFERON-TB Gold Plus Test results during the COVID-19 pandemic.PloS one · 2025Article
- Association between ambient particulate matter and latent tuberculosis infection among 198 275 students.Journal of global health · 2024Article
- Article
- Molecular and microbiological methods for the identification of nonreplicating Mycobacterium tuberculosis.PLoS pathogens · 2024Review
- Splenic marginal zone B cells restrict Mycobacterium tuberculosis infection by shaping the cytokine pattern and cell-mediated immunity.Cell reports · 2024Article
- Investigating the Diagnostic and Therapeutic Potential of a T Cell Receptor (TCR)-like single Domain Antibody (sDAb)-Human IgG1 Antibody against Heat Shock Protein (HSP) 16KDa/HLA-A2 for Latent Tuberculosis.Tropical medicine and infectious disease · 2024Article
69 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The aim of this review is to present the current state of knowledge on human latent tuberculosis infection (LTBI) based on clinical studies and observations, as well as experimental in vitro and animal models. Several key terms are defined, including "latency," "persistence," "dormancy," and "antibiotic tolerance." Dogmas prevalent in the field are critically examined based on available clinical and experimental data, including the long-held beliefs that infection is either latent or active, that LTBI represents a small population of nonreplicating, "dormant" bacilli, and that caseous granulomas are the haven for LTBI. The role of host factors, such as CD4(+) and CD8(+) T cells, T regulatory cells, tumor necrosis factor alpha (TNF-α), and gamma interferon (IFN-γ), in controlling TB infection is discussed. We also highlight microbial regulatory and metabolic pathways implicated in bacillary growth restriction and antibiotic tolerance under various physiologically relevant conditions. Finally, we pose several clinically important questions, which remain unanswered and will serve to stimulate future research on LTBI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.